Louise Emmett, MD, discusses the ENZA-p trial which studied enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617.
RLT
Advertisement
Latest News
The addition of ipi/nivo to LuPSMA improved PSA-PFS over 12 months in patients with mCRPC.
18F-flotufolastat-PET can help determine severe hematologic toxicity in patients with mCRPC who are treated with 177Lu.
Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy.
Dr. Kishan reviews current evidence supporting the use of PSMA RLT in patients with oligometastatic disease.
177Lu vipivotide tetraxetan is the only PSMA-targeted agent to significantly improve rPFS with a tolerable safety profile.
Dr. Morris discusses trials and rationale behind using PSMA therapy earlier in prostate cancer treatment.
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Braun showcases an ongoing phase 1/2 trial of the HPKI inhibitor NDI-101150 in clear cell renal cell carcinoma.
Dr. Braun details an integrative analysis of the Checkmate 9ER trial that highlights both circulating and TME biomarkers.
Dr. Zhang gives an update on the PDIGREE trial, including new information on tolerability and treatment response.
High KIM-1 may be a biomarker of poor prognosis in RCC and correlates with specific LOF mutations, transcriptions programs.
68Ga-NY104 detected using PET/CT shows better diagnostic efficacy than 18F-FDG PET/CT in patients with mccRCC.
Researchers studied clonal hematopoiesis mutations in patients treated with 177Lu-PSMA-617 or cabazitaxel for prostate cancer
Advertisement
Section Editor
Scott Tagawa, MD, MS, FACPProfessor of Medicine and Urology | Weill Cornell Medicine
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.